TD Asset Management Inc raised its holdings in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 2.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,112,841 shares of the company’s stock after acquiring an additional 23,229 shares during the quarter. TD Asset Management Inc’s holdings in Astrazeneca were worth $195,304,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of AZN. Triumph Capital Management bought a new stake in Astrazeneca during the third quarter valued at about $25,000. Bangor Savings Bank raised its holdings in Astrazeneca by 102.7% during the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after acquiring an additional 154 shares during the period. Eagle Bay Advisors LLC bought a new stake in Astrazeneca during the fourth quarter valued at about $30,000. YANKCOM Partnership bought a new stake in Astrazeneca during the fourth quarter valued at about $31,000. Finally, TFC Financial Management Inc. raised its holdings in Astrazeneca by 3,350.0% during the fourth quarter. TFC Financial Management Inc. now owns 345 shares of the company’s stock valued at $32,000 after acquiring an additional 335 shares during the period. 20.35% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Several equities research analysts have recently issued reports on the company. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a report on Monday. UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a report on Thursday, May 21st. DZ Bank raised Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Finally, Weiss Ratings assumed coverage on Astrazeneca in a report on Wednesday, March 11th. They issued a “buy (b)” rating on the stock. Twelve research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $205.33.
Astrazeneca Trading Up 3.1%
Shares of AZN stock opened at $181.72 on Friday. Astrazeneca Plc has a 12-month low of $137.23 and a 12-month high of $212.71. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The stock’s 50-day moving average price is $190.77 and its 200-day moving average price is $184.71. The stock has a market capitalization of $281.83 billion, a price-to-earnings ratio of 27.29, a price-to-earnings-growth ratio of 1.51 and a beta of 0.25.
Astrazeneca (NYSE:AZN – Get Free Report) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.52 by $0.06. The company had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. Equities research analysts predict that Astrazeneca Plc will post 9.52 EPS for the current fiscal year.
About Astrazeneca
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Further Reading
- Five stocks we like better than Astrazeneca
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
- Medtronic Bottoms, Healthy Rebound Ahead
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
